Latest news with #BPH
Time of India
3 days ago
- Health
- Time of India
Vadodara man undergoes UroLift procedure for enlarged prostate
Vadodara: A 57-year-old man underwent the UroLift procedure — a minimally invasive treatment for an enlarged prostate — marking the first time the technique was performed in Vadodara. The patient had been experiencing difficulty in urination and was initially treated with medication for prostate enlargement. "He was suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate, a progressive condition that affects many men as they age," said Dr Haresh Thummar, Senior Consultant Urologist at Zydus Hospitals, Vadodara. If left untreated, BPH can cause permanent bladder damage and, in some cases, may result in urinary retention, requiring catheterization. "He had been on medication for nearly four years. However, over the past couple of months, his response to different prostate drugs had diminished. He continued to struggle with poor urine flow, significantly impacting his quality of life," Thummar added. Doctors considered traditional endoscopic prostate surgery. "Procedures like transurethral resection of the prostate (TURP) and laser surgery are commonly used to treat BPH. However, both carry a risk of sexual dysfunction, including retrograde ejaculation or complete absence of ejaculation. The patient was deeply concerned about preserving his sexual function along with improving urinary health," said Thummar. Given these concerns, doctors chose the UroLift procedure — a minimally invasive technique using special clips inserted into the prostate to lift and hold enlarged tissue away from the urethra, thereby relieving obstruction and improving urine flow. "The patient underwent the UroLift procedure, which was performed for the first time in Vadodara. Once the catheter was removed, he was able to urinate normally," Thummar said. Post-surgery, a uroflowmetry test (which measures urine flow rate and volume) showed that the patient's maximum flow rate improved from 9 ml/sec to 20.7 ml/sec.
Business Upturn
24-06-2025
- Business
- Business Upturn
Coherent Launches ACE FL, an All-New, Two-Micron Fiber Laser to Address the Expanding Opportunities in Urology and Other Medical Markets
By GlobeNewswire Published on June 25, 2025, 01:35 IST SAXONBURG, Pa., June 24, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its ACE FL series, thulium fiber laser (TFL), engineered specifically for therapeutic medical applications – most notably for lithotripsy and benign prostatic hyperplasia (BPH) treatment. The new two-micron ACE FL system delivers superior precision, improved patient outcomes, and enhanced procedural efficiency compared to legacy laser technologies such as holmium:YAG systems. It is optimized for integration into surgical devices and laser systems used in minimally invasive procedures. 'Our new thulium fiber laser is a breakthrough platform that enables medical OEMs to deliver safer, faster, and more effective treatments for kidney stones and BPH,' said Martin Seifert, Vice President, High-Power Fiber Laser Business Unit at Coherent. 'With the growing shift toward outpatient and minimally invasive procedures, the market opportunity for fiber-based surgical lasers is stronger than ever.' Thulium fiber lasers offer superior cutting precision in BPH enucleation, a compact form factor ideal for OEM integration, and enhanced energy efficiency through lower power consumption and improved thermal management. The ACE FL platform leverages proprietary fiber designs and manufacturing capabilities to offer OEM partners a scalable, high-performance solution for next-generation surgical tools. In addition, Coherent enhances rapid ease of integration by multiplying the power of our new ACE FL series with the surgically proven capabilities of our superb range of disposable fiber assemblies. With vertically integrated manufacturing and IP-protected fiber designs, Coherent is uniquely positioned to support global medical device manufacturers with reliable supply and long-term innovation. Coherent will showcase the ACE FL at LASER World of Photonics Munich 2025. About Coherent Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at Media Contact : [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
24-06-2025
- Business
- Yahoo
Coherent Launches ACE FL, an All-New, Two-Micron Fiber Laser to Address the Expanding Opportunities in Urology and Other Medical Markets
SAXONBURG, Pa., June 24, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its ACE FL series, thulium fiber laser (TFL), engineered specifically for therapeutic medical applications – most notably for lithotripsy and benign prostatic hyperplasia (BPH) treatment. The new two-micron ACE FL system delivers superior precision, improved patient outcomes, and enhanced procedural efficiency compared to legacy laser technologies such as holmium:YAG systems. It is optimized for integration into surgical devices and laser systems used in minimally invasive procedures. 'Our new thulium fiber laser is a breakthrough platform that enables medical OEMs to deliver safer, faster, and more effective treatments for kidney stones and BPH,' said Martin Seifert, Vice President, High-Power Fiber Laser Business Unit at Coherent. 'With the growing shift toward outpatient and minimally invasive procedures, the market opportunity for fiber-based surgical lasers is stronger than ever.' Thulium fiber lasers offer superior cutting precision in BPH enucleation, a compact form factor ideal for OEM integration, and enhanced energy efficiency through lower power consumption and improved thermal management. The ACE FL platform leverages proprietary fiber designs and manufacturing capabilities to offer OEM partners a scalable, high-performance solution for next-generation surgical tools. In addition, Coherent enhances rapid ease of integration by multiplying the power of our new ACE FL series with the surgically proven capabilities of our superb range of disposable fiber assemblies. With vertically integrated manufacturing and IP-protected fiber designs, Coherent is uniquely positioned to support global medical device manufacturers with reliable supply and long-term innovation. Coherent will showcase the ACE FL at LASER World of Photonics Munich 2025. About Coherent Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at Media Contact: innovations@
Irish Examiner
24-06-2025
- Health
- Irish Examiner
Cork medical firm Healthcare 21 set to introduce new procedure to treat enlarged prostate
An innovative robotic procedure for treating men with enlarged prostates will be made available to patients in Ireland through Cork medical company Healthcare 21. Healthcare 21 which is headquartered in Blarney in Co Cork employs 340 people in Ireland and is partnering with Procept BioRobotics to bring the new treatment to Ireland. The aquablation therapy is a robotically assisted, minimally invasive procedure which uses a high-speed water jet to precisely remove prostate tissue and treat Benign Prostatic Hyperplasia (BPH), commonly referred to as an enlarged prostate, which affects half of men aged 51 to 60 in Ireland. The new treatment is being offered at Ulster Hospital in Belfast, with Healthcare 21 introducing the technology to the South. The Blarney-headquartered healthcare solutions firm is believed to be in discussion with a number of private hospitals in the south to roll out the technology to patients in the Republic of Ireland. "By leveraging innovative treatments like Aquablation therapy, we can help alleviate long waiting lists in a healthcare sector experiencing unprecedented demand," said Jackie Knox, business manager of Healthcare 21. "This minimally invasive procedure doubles the efficiency of the surgical team, allowing more patients to be treated in a single theatre list. Additionally, it enables 90% of patients to be discharged the same day, reducing the need for elective beds. "We are thrilled to collaborate closely with Ulster Hospital, enabling surgeons to manage complex anatomy and larger prostates, thereby allowing senior surgeons to focus on other procedures. Establishing the robotic procedure in Belfast will provide access for other hospitals to use Belfast as a robotic centre, helping to reduce backlogs in the surrounding region."
Sky News AU
14-06-2025
- Health
- Sky News AU
Medical experts unveil major clues to the type of "incurable" cancer King Charles could have been diagnosed with
Since Buckingham Palace confirmed King Charles had cancer in 2024, medical professionals around the globe have tried to determine exactly which type of disease he has. The palace said "diagnostic tests" found Charles' cancer during a "corrective" hospital procedure for a benign prostate enlargement, known as Benign Prostatic Hyperplasia (BPH), in a statement last February. BPH is characterised by an overgrowth of prostate tissue that pushes against the urethra and the bladder, restricting the flow of urine. Buckingham Palace has not disclosed what type of cancer the King has or what stage the disease is at while he continues to undergo treatment. However, it's been confirmed he does not have prostate cancer despite the initial hospital procedure being for an enlarged prostate. While the corrective procedure the King had is unknown, the most common one for BPH is Transurethral Resection of the Prostate (TURP). According to the Mayo Clinic, TURP involves a surgeon trimming away extra prostate tissue that is blocking the flow of urine. A transurethral ultrasound ablation (TULSA) is another treatment option for BPH. This innovative procedure is performed under MRI guidance, using targeted ultrasound waves to heat and destroy prostate tissue. Since Both TURP and TULSA involve removing prostate tissues, Profound Medical, which develops the TULSA device, suggests Charles could have bladder or kidney cancer after doctors examined his removed tissue. "The nature of King Charles's diagnosis is not uncommon and is referred to as an incidental diagnosis," Profound Medical said on its website. "This can occur when treatment for conditions like BPH leads to the unexpected discovery of other illnesses. "During procedures intended to relieve BPH symptoms, physicians might take the opportunity to examine removed tissue or conduct imaging tests that can reveal other conditions like bladder or kidney cancer or even unrelated cancers identified through routine imaging." According to the Cleveland Clinic, examining tissue from the prostate can also detect urethral cancer. The medical centre states people older than 60 who are males are more likely to get this cancer type. Moreover, data by Cancer Research UK suggests King Charles could have lung cancer or bowel cancer. The data states the most common cancers in UK males after prostate cancer (28 percent) are lung cancer (13 per cent) and bowel cancer (12 per cent) from 2017 through 2019. It also states head and neck, bladder, oesophageal cancers, and leukaemia are among the UK's ten most common cancers in males. The Cancer Council encourages men over the age of 50 to get tested for bowel cancer every two years. The palace continues to say the monarch is doing well, but veteran royal insider Camilla Tonminey said Charles' diagnosis is ultimately incurable. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' Ms Tonminey recently told The Telegraph. She said 'tentative' planning for Charles' 80th birthday celebrations in 2028 is going ahead with the expectation the King's cancer will continue to be managed. For the second consecutive year, Charles will not ride by horseback and will instead opt to go by carriage at Trooping the Colour on Saturday, according to The Times. The carriage was deemed a safer and more comfortable option at the King's official birthday parade last year after the King's procedure.
